GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain FDA approval by 2026.

With a GLP-1 in pill form for weight loss expected to be FDA-approved by year’s end, obesity medicine physicians said they are gearing up for higher demand and already answering questions about ...

New study reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Here's what they found.

MindRank has shared the skinny on its oral GLP-1 receptor agonist, publishing data from a Chinese phase 2b obesity trial that suggests efficacy is in the same ballpark as Eli Lilly’s orforglipron.